SCHEMBL611015

SCHEMBL611015

COc1ccc(CNc2ccc([N+](=O)[O-])c3nonc23)cc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.72
MEN1 O00255 6/20 0.72
USP2 O75604 1/20 0.72
HTT P42858 1/20 0.72
RECQL P46063 1/20 0.72
IDO1 P14902 4/20 0.69
KDM4E B2RXH2 1/20 0.59
ALDH1A1 P00352 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
MIF P14174 1/20 0.58
NPC1 O15118 3/20 0.57
RAB9A P51151 2/20 0.57
GSTM2 P28161 1/20 0.53
MAPT P10636 1/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
MYC P01106 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25343177 0.84 MEN1 (0.77) KMT2AMEN1USP2HTTRECQL
SCHEMBL443977 0.84 MEN1 (1.00) KMT2AMEN1USP2HTTRECQL
SCHEMBL300125 0.81 IDO1 (1.00) KMT2AMEN1HTTIDO1ALDH1A1
SCHEMBL5457508 0.81 NPC1 (0.50) KMT2AMEN1USP2HTTRECQL
SCHEMBL4309629 0.78 MAPT (0.62) KMT2AMEN1KDM4EALDH1A1SMN1; SMN2
SCHEMBL17781757 0.78 MEN1 (0.67) KMT2AMEN1USP2HTTRECQL
SCHEMBL298137 0.76 GSTP1 (0.72) IDO1GSTM2
SCHEMBL28069116 0.76 GSTM2 (0.68) KMT2AMEN1USP2HTTRECQL
SCHEMBL7318993 0.76 MAPT (0.68) KMT2AMEN1KDM4EALDH1A1SMN1; SMN2
SCHEMBL22705040 0.75 IDO1 (0.55) KMT2AMEN1USP2HTTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3965738-B1 METHOD FOR PRODUCTION OF LIPOSOMES UNIV DO MINHO (PT) 2025-08-06 EP disclosed
US-20220241203-A1 METHOD FOR PRODUCTION OF LIPOSOMES UNIVERSIDADE DO MINHO (PT) 2022-08-04 US disclosed
EP-3283879-B1 METHOD FOR DETECTING ONE OR MORE ANALYTES IN A SAMPLE, SAID DETECTION BEING DELIMITED BY A REACTION CHAMBER ATTOMOL GMBH MOLEKULARE DIAGNOSTIKA (DE) 2019-03-27 EP disclosed
EP-3283879-A1 METHOD FOR DETECTING ONE OR MORE ANALYTES IN A SAMPLE, SAID DETECTION BEING DELIMITED BY A REACTION CHAMBER Attomol GmbH Molekulare Diagnostika (DE) 2018-02-21 EP disclosed
WO-2016166295-A1 METHOD FOR DETECTING ONE OR MORE ANALYTES IN A SAMPLE, SAID DETECTION BEING DELIMITED BY A REACTION CHAMBER ATTOMOL GMBH MOLEKULARE DIAGNOSTIKA (DE) 2016-10-20 WO disclosed
EP-2167964-B1 METHOD FOR CARRYING OUT AND EVALUATING MIX&MEASURE ASSAYS FOR THE MEASUREMENT OF REACTION KINETICS, CONCENTRATIONS AND AFFINITIES OF ANALYTES IN MULTIPLEX FORMAT ATTOMOL GMBH MOLEKULARE DIAGNOSTIKA (DE) 2015-03-11 EP disclosed
US-20120122896-A1 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION PIKE PHARMA GMBH (CH) 2012-05-17 US disclosed
US-20120039813-A1 INTRINSICALLY COLORED, LUMINESCENT SILK FIBROIN AND A METHOD OF PRODUCING THE SAME AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2012-02-16 US disclosed
US-20110275523-A1 METHODS AND KITS FOR ANALYZING POLYNUCLEOTIDE SEQUENCES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2011-11-10 US disclosed
US-7981604-B2 Methods and kits for analyzing polynucleotide sequences CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2011-07-19 US disclosed
EP-0250119-A2 Atherosclerotic anti-idiotype antibody immunoassay and reagents VASOCOR (US) 1987-12-23 EP disclosed
EP-0248630-A2 Atherosclerotic plaque antigen immunoassay VASOCOR (US) 1987-12-09 EP disclosed
EP-0124103-A2 Fluorometric assay of chymopapain and reagents therefor BioWhittaker, Inc. (US) 1984-11-07 EP disclosed
US-4277437-A CHEMILUMINESCENT SOURCE, QUENCHER MOLECULE SYVA COMPANY (US) 1981-07-07 US disclosed
US-4235869-A ANTIBODY FRAGMENTS MONOVALENT RECEPTOR SYVA COMPANY (US) 1980-11-25 US disclosed
US-4233402-A CHEMICAL ANALYSIS OF A BINDING PAIR OF LIGANDS AND ENZYMES BY LIGHT SIGNALS SYVA COMPANY (US) 1980-11-11 US disclosed
US-4220450-A Chemically induced fluorescence immunoassay SYVA COMPANY (US) 1980-09-02 US disclosed
US-4199559-A DETERMINING THE PRESENCE OR AMOUNT OF A LIGAND OR ANTIBODIES SYVA COMPANY (US) 1980-04-22 US disclosed
US-4174384-A Fluorescence quenching with immunological pairs in immunoassays SYVA COMPANY (US) 1979-11-13 US disclosed
US-3996345-A Fluorescence quenching with immunological pairs in immunoassays SYVA COMPANY (US) 1976-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122896-A1 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION TENT4B, IRF3, MAVS KMT2A 1674/4885MEN1 4597/4885USP2 1795/4885
US-20120039813-A1 INTRINSICALLY COLORED, LUMINESCENT SILK FIBROIN AND A METHOD OF PRODUCING THE SAME IK, FGB, VIP KMT2A 4547/4885MEN1 1459/4885USP2 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.